

1 **Inhibition of the beta-1 adrenergic receptor does not potentiate mirabegron-stimulated**
2 **human brown adipose tissue thermogenesis.**

3 Lauralyne Dumont^{1,2}, Alexandre Caron^{3,4,5}, Gabriel Richard⁶, Etienne Croteau⁶, Mélanie Fortin¹,
4 Frédérique Frisch¹, Serge Phoenix^{1,6}, Stéphanie Dubreuil¹, Brigitte Guérin⁶, Éric E. Turcotte⁶,
5 André C. Carpentier^{1,7}, Denis P. Blondin^{1,8,#}.

6
7 ¹Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC,
8 Canada.

9 ²Department of Physiology-Pharmacology, Université de Sherbrooke, Sherbrooke, QC, Canada.

10 ³Faculty of Pharmacy, Université Laval, Quebec City, QC, Canada.

11 ⁴Quebec Heart and Lung Institute, Quebec City, QC, Canada.

12 ⁵Montreal Diabetes Research Center, Montreal, QC, Canada.

13 ⁶Department of Nuclear Medicine and Radiobiology, Centre d’Imagerie Moléculaire de
14 Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada.

15 ⁷Department of Medicine, Division of endocrinology, Université de Sherbrooke, Sherbrooke,
16 QC, Canada

17 ⁸Department of Medicine, Division of neurology, Université de Sherbrooke, Sherbrooke, QC,
18 Canada

19
20 #Corresponding author

21
22 **Running Head:**

23
24 **Word count** Main Text: 3,316 Abstract: 148

25 **Number of tables: 2**

26 **Number of figures: 4**

27
28 **Address correspondence to:**

Dr. Denis P. Blondin	29
Centre de recherche du CHUS	30
3001, 12e Avenue Nord	31
Sherbrooke, Québec, Canada K1N 6N5	32
Tel: 819.346.1110 ext. 15243	33
Fax: 819.564.5445	34
e-mail: denis.p.blondin@usherbrooke.ca	35

36
37 **Conflict of interest: The authors have declared that no conflict of interest exists related to the content of this manuscript.**

1 **ABSTRACT**

2 Pharmacological stimulation of human brown adipose tissue (BAT) has been hindered by either
3 ineffective activation or undesirable off-target secondary effects. Oral administration of the
4 maximal allowable dose of mirabegron (200 mg), a β_3 -adrenergic receptor (β_3 -AR) agonist, has
5 been effective in stimulating BAT thermogenesis and whole-body energy expenditure. However,
6 this too has been accompanied by undesirable cardiovascular effects. Combining mirabegron with
7 a cardio-selective β_1 -AR antagonist could not only suppress these unwanted effects, but potentially
8 increase the sensitivity of the β_3 -AR and β_2 -AR in WAT and BAT. Here we report that co-ingesting
9 a high dose of the β_1 -AR antagonist bisoprolol with mirabegron suppresses the increase in heart
10 rate, systolic blood pressure and myocardial oxygen consumption. However, it also blunted the
11 mirabegron-stimulated increase in BAT lipolysis, thermogenesis and glucose uptake. Whether the
12 attenuation in BAT blood flow induced by the large dose of bisoprolol limited BAT thermogenesis
13 remains to be determined.

14 clinicaltrials.gov (NCT04823442)

15

16

17 **Key Words :** brown adipose tissue, thermogenesis, positron emission tomography, adrenergic
18 receptor, stable isotope, adipose tissue, energy metabolism.

1 INTRODUCTION

2 The stimulation of brown adipose tissue (BAT) thermogenesis has long been touted as an
3 attractive therapeutic target for the prevention or treatment of obesity and its cardiometabolic
4 complications. This stems primarily from the large body of work in preclinical models, which
5 robustly demonstrate the energy dissipating capacity of BAT following cold or pharmacological
6 stimulation ¹⁻⁵. However, evidence for BAT functioning in such a capacity remains controversial
7 ⁶ and largely associative in humans ^{7,8}. Some of the barriers in understanding the therapeutic
8 potential of human BAT relates to the stimuli used to activate BAT thermogenesis, which often
9 simultaneously recruits other thermogenic mechanisms. For instance, much of what is known
10 about human BAT function comes from cold-stimulated conditions, where thermogenesis and
11 substrate clearance is primarily driven by shivering skeletal muscles ⁹⁻¹², even under very mild
12 conditions ¹³. Alternatively, the recent repurposing of the β_3 -adrenergic receptor (β_3 -AR) agonist
13 mirabegron, a medication used to treat overactive bladder (OAB), has provided the opportunity to
14 isolate the metabolic effects of targeting BAT more specifically given its high affinity for the
15 human β_3 -AR compared to the β_2 - or β_1 -AR (105-fold greater affinity for β_3 -AR than β_1 -AR, and
16 33-fold stronger than β_2 -AR).

17 The initial investigations using mirabegron to stimulate BAT revealed two important trends
18 ¹⁴⁻¹⁸. First, stimulating BAT thermogenesis required a dosage that was four-times higher than the
19 maximum approved dosage (approved for 50 mg daily) ¹⁹. Only when mirabegron was ingested at
20 the maximal allowable dose (200 mg) in lean healthy men did whole-body energy expenditure and
21 BAT glucose uptake increase ^{17,19}. Furthermore, only the high dose of mirabegron increased BAT
22 oxidative metabolism compared to room temperature, levels that remained significantly lower than
23 what is observed during mild cold exposure ¹⁹. Secondly, such a high dose of mirabegron led to

1 nonselective β -AR activation, resulting in an increase in cardiovascular responses (β_1 -AR-
2 mediated) and white adipose tissue (WAT) lipolysis (primarily β_2 -AR-mediated). Indeed, both
3 heart rate and systolic blood pressure increased when given the maximal allowable dose of
4 mirabegron, consistent with the secondary effects reported in the early mirabegron clinical trials
5 for the treatment of OAB²⁰⁻²². In humans, the heart expresses mainly the β_1 -AR^{23,24} while brown
6 adipocytes express mainly the β_2 -AR and β_1 -AR and very low levels of β_3 -AR^{19,25,26}. This explains
7 why, despite its high affinity for the β_3 -AR, mirabegron may still bind to the β_2 -AR and β_1 -AR to
8 stimulate thermogenesis. We also recently showed that silencing the gene encoding the β_2 -AR
9 (*ADRB2*) *in vitro*, resulted in a compensatory increase in the expression of the gene encoding the
10 β_3 -AR (*ADRB3*)¹⁹. Similarly, others have shown that silencing the gene encoding for the β_1 -AR
11 (*ADRB1*) significantly increases brown/beige adipocyte oxygen consumption, despite decreasing
12 *UCPI* expression²⁷. In light of these findings, the primary aim of this study was to examine
13 whether administration of the maximal allowable dose of mirabegron when combined with a
14 cardio-selective β_1 -AR antagonist, bisoprolol, could increase the sensitivity of the β_3 -AR and β_2 -
15 AR in WAT and BAT while suppressing the unwanted cardiovascular effects that present with the
16 administration of high doses of mirabegron. Thus, we hypothesized that administration of
17 mirabegron with a β_1 -AR receptor antagonist could block cardiovascular effects while increasing
18 BAT thermogenesis above levels observed when mirabegron is administered alone.

19

20

1 **RESULTS**

2 **The Beneficial Metabolic Responses Induced by Mirabegron Are Attenuated by Bisoprolol**

3 The main purpose of this study was to compare the stimulation of BAT metabolism using
4 mirabegron without or with a β_1 -AR antagonist in 8 lean healthy individuals (Table 1, Figure 1).
5 We hypothesized that the acute oral administration of the maximal allowable dose of mirabegron
6 (200 mg) with the β_1 -AR antagonist, bisoprolol (10 mg), would result in an increase in BAT
7 oxidative metabolism and whole-body energy expenditure without the adverse cardiovascular
8 events observed when a high dose of mirabegron is administered alone. The primary outcome
9 measures of this clinical study as entered in clinicaltrials.gov (NCT04823442) included the change
10 in activation of BAT (oxidative metabolism and blood flow) and BAT net glucose uptake.
11 Secondary endpoints can be found at <https://clinicaltrials.gov/ct2/show/NCT04823442> .

12 Using liquid chromatography-tandem mass spectrometry we first examined the plasma
13 pharmacokinetics of mirabegron without (M) or with bisoprolol (MB) in the participants. The
14 study was designed to ensure that the time of maximal plasma mirabegron concentrations
15 coincided with our dynamic list-mode PET acquisition which was 240 minutes after oral
16 administration of the mirabegron without or with bisoprolol (Table 2 and Figure 2A; Median: M:
17 180 min; MB: 240 min). Compared to baseline measures, oral administration of either mirabegron
18 alone or in combination with bisoprolol increased resting energy expenditure by 27% ($+18.2 \pm 6.7$
19 kcal/h; $P < 0.0001$) and 11% ($+7.4 \pm 8.1$ kcal/h; $P = 0.0268$), respectively (Figure 2B; Table 2).
20 However, the resting energy expenditure was significantly lower when mirabegron was co-
21 ingested with bisoprolol compared to when it was ingested alone (Figure 2 C; $P = 0.0402$).

22 A multi-tracer approach with [^{11}C]acetate and the [^{18}F]FDG was used to evaluate the rate of BAT
23 oxidative metabolism and tissue-specific glucose uptake. A four-compartment, two-tissue

1 pharmacokinetic model for [^{11}C]acetate in BAT²⁸ was applied to derive the rates of [^{11}C]acetate
2 uptake (K_1 , $\text{mL}\cdot\text{g}^{-1}\cdot\text{min}^{-1}$), a marker of tissue perfusion, oxidative metabolism (k_2 , min^{-1}) and lipid
3 synthesis (k_3 , min^{-1}). The rate of BAT [^{11}C]acetate uptake increased with mirabegron alone (Figure
4 2D; $P = 0.0511$), which was accompanied by a 2.7-fold increase in BAT oxidative metabolism
5 (Figure 2E; from $0.636 \pm 0.251 \text{ min}^{-1}$ at room temperature to $1.629 \pm 1.097 \text{ min}^{-1}$ with mirabegron
6 alone, $P = 0.0421$). Nevertheless, BAT oxidative metabolism was not significantly different when
7 the mirabegron was co-ingested with the bisoprolol compared to control room temperature
8 conditions (Figure 2E; from $0.636 \pm 0.251 \text{ min}^{-1}$ at room temperature to $1.273 \pm 0.651 \text{ min}^{-1}$). We
9 found that mirabegron without or with bisoprolol did not elicit a significant increase in BAT
10 intracellular lipid synthesis (Figure 2F), nor elicit a difference in the change in CT-derived tissue
11 radiodensity, which represents a marker of changes in intracellular triglyceride content (Figure
12 2G). Using the Patlak linearization model, we showed that the high dose of mirabegron increased
13 the rate of BAT glucose uptake, but was significantly lower when combined with bisoprolol ($24 \pm$
14 $10 \text{ nmol}\cdot\text{g}^{-1}\cdot\text{min}^{-1}$ with mirabegron alone vs. $16 \pm 8 \text{ nmol}\cdot\text{g}^{-1}\cdot\text{min}^{-1}$ with mirabegron and bisoprolol;
15 $P = 0.0284$). Although the rate of BAT glucose uptake was lower when mirabegron was given with
16 bisoprolol, it remained significantly greater than what has previously been reported under room
17 temperature conditions [$9 \pm 4 \text{ nmol}\cdot\text{g}^{-1}\cdot\text{min}^{-1}$, $N = 27$; $P = 0.0018^{29}$]. We did not observe any
18 differences in net glucose uptake in subcutaneous WAT (scWAT; $12 \pm 7 \text{ nmol}\cdot\text{g}^{-1}\cdot\text{min}^{-1}$ with
19 mirabegron alone vs. $13 \pm 4 \text{ nmol}\cdot\text{g}^{-1}\cdot\text{min}^{-1}$ with mirabegron combined with bisoprolol) or skeletal
20 muscles (from $11 \pm 6 \text{ nmol}\cdot\text{g}^{-1}\cdot\text{min}^{-1}$ with mirabegron alone vs. $10 \pm 1 \text{ nmol}\cdot\text{g}^{-1}\cdot\text{min}^{-1}$ with
21 mirabegron combined with bisoprolol) between the two conditions (Figure 2H).

22 **Bisoprolol Suppressed Cardiovascular Secondary Effects of Mirabegron**

1 It has previously been demonstrated that administration of high doses of mirabegron leads to
2 unwanted cardiovascular effects, likely mediated through a cross-activation of the β_1 -AR^{17,18,30,31}.
3 These undesirable effects are what prompted us to assess cardiovascular outcomes when
4 combining mirabegron with the cardioselective β_1 -AR antagonist, bisoprolol³². Mirabegron alone
5 increased systolic blood pressure by 5 ± 5 mmHg above baseline levels. In contrast, when
6 mirabegron was combined with bisoprolol, systolic blood pressure decreased below baseline levels
7 by 6 ± 10 mmHg (Figure 3A, $P = 0.0252$). Diastolic blood pressure decreased by 3 ± 6 mmHg and
8 4 ± 19 mmHg below pre-treatment levels with mirabegron alone or with bisoprolol, respectively,
9 with no significant difference between the two conditions (Figure 3B). Mirabegron given alone
10 increased heart rate by 6 ± 7 beats·min⁻¹ ($P = 0.0565$) above pre-treatment levels, whereas
11 mirabegron administered with bisoprolol decreased heart rate by 5 ± 6 beats·min⁻¹ ($P = 0.1302$)
12 below the pre-treatment levels (Figure 3C, $P = 0.0081$). To examine the effects of mirabegron with
13 or without bisoprolol on the myocardial metabolic demands, we calculated the rate pressure
14 product (RPP). While RPP increased significantly by 972 ± 927 mmHg·bpm above pre-treatment
15 levels ($P = 0.0333$) when given mirabegron alone, it decreased by 1548 ± 1158 mmHg·bpm
16 compared to pre-treatment levels when mirabegron was administered with bisoprolol ($P = 0.0544$)
17 which was significantly different between the two conditions (Figure 3D, $P = 0.0005$).

18 As result of the large field of view of the PET scanner (26 cm), it was possible for the first time to
19 simultaneously quantify BAT thermogenesis and myocardial oxygen consumption in humans.
20 Myocardial blood flow (F), tracer uptake (K_1) and oxidative metabolism (k_2) were assessed by
21 [¹¹C]acetate PET in three segments of the heart vascularized by the left anterior descending artery
22 (LAD), left circumflex artery (LCX), and right coronary artery (RCA) as well as globally (total),
23 pre- and post-treatment (Figure 3E, 3F, and 3G). In order to do this, we analyzed PET dynamic

1 images of the heart with the PMOD cardiac PET modeling tool, PCARDP (PMOD Technologies,
2 version 3.7). However, since the PET scanner has a limited field of view and participants varied
3 in height, we prioritized PET image acquisition of supraclavicular BAT at the expense of having
4 the complete image of the heart. Therefore, we have a limited number of PET images for the
5 analysis of the heart, which did not allow a complete statistical analysis. However, based on the
6 [¹¹C]acetate data, myocardial blood flow did not appear to be affected by mirabegron, whether
7 administered alone or with bisoprolol, when compared to pre-treatment conditions, in all the
8 regions of the heart (Figure 3E). The [¹¹C]acetate uptake in the heart increased when given
9 mirabegron compared to pre-treatment levels and increased further in combination with the
10 bisoprolol (Figure 3F). The oxidative metabolism of the three segments of the myocardium as well
11 as global myocardium oxidative metabolism were more elevated in the pre-treatment condition
12 and when mirabegron was given alone compared to the administration of mirabegron with
13 bisoprolol. The reduction in oxidative metabolism when mirabegron was administered in
14 combination with bisoprolol is consistent with the reduction in RPP, which is commonly used as
15 an index of myocardial oxygen consumption^{33,34}.

16 **Mirabegron Without or With Bisoprolol Did Not Alter White Adipose Tissue Lipolysis**

17 Since the high dose of mirabegron leads to nonselective β -AR activation, we assessed white
18 adipose tissue (WAT) lipolysis which is primarily driven by β_2/β_1 -AR signaling. To examine this
19 response we used continuous infusion of [U-¹³C]palmitate and [1,1,2,3,3-²H⁵]-glycerol to
20 determine the rate of systemic appearance of NEFA and glycerol (indicator of whole-body WAT
21 lipolysis) (Figure 4A-4D). The systemic appearance rate (R_a) of glycerol ($R_{a\text{glycerol}}$) and NEFA
22 ($R_{a\text{NEFA}}$) did not increase significantly (Figure 4A-4D). However, compared to the baseline period,
23 the rate of fatty acid oxidation increased significantly both when mirabegron was given alone (P

1 = 0.0021) and when given in combination with bisoprolol ($P = 0.0038$) (Figure 4F), however there
2 was no significant difference between the two conditions. In steady-state conditions, the difference
3 between the total fatty acids released upon intracellular hydrolysis of triglycerides ($3 \times R_{a_{\text{glycerol}}}$)
4 and the rate of total fatty acid oxidation (calculated from indirect calorimetry) indicate the whole-
5 body rate of fatty acid re-esterification, as this is primarily its alternative metabolic fate. Since the
6 increase in both the rate of whole-body lipolysis and fatty acid oxidation were not different whether
7 mirabegron was given alone or with bisoprolol, this suggests that there was no difference in fatty
8 acid re-esterification between the two groups (Figure 4I). Indeed, there was no change in the re-
9 esterification of the fatty acids at the primary site of lipolysis (intracellular cycling) or following
10 their transit in circulation where they can be taken up by the liver to be stored in intracellular lipid
11 droplets or incorporated into VLDL (extracellular cycling) (Figure 4I).

12

13 **DISCUSSION**

14 The ingestion of the β_3 -AR agonist mirabegron at the maximal allowable dose (200 mg)
15 increases BAT thermogenesis but also leads to an adverse overstimulation of cardiovascular
16 responses, likely by stimulating all three β -AR subtypes^{17,18,30,31}. Here we show that combining
17 the administration of mirabegron with a cardioselective β_1 -AR antagonist (bisoprolol; 15-fold
18 more selective for β_1 -AR vs β_2 -AR and 31-fold more selective for β_1 -AR vs β_3 -AR³⁵), to suppress
19 these cardiovascular responses, did not increase BAT oxidative metabolism, and in fact reduced
20 BAT blood flow. This was also accompanied by a reduction in the rate of BAT glucose uptake.
21 By design, bisoprolol did indeed inhibit the mirabegron-stimulated increase in systolic blood
22 pressure and heart rate. It is unclear whether the attenuation of systemic and BAT blood flow

1 induced by the relatively large dose of bisoprolol used may have contributed to the impaired BAT
2 thermogenesis.

3 Previously, we showed that oral administration of the maximal allowable dose of
4 mirabegron (200 mg) increases BAT oxidative metabolism on average 2.1-fold above basal
5 conditions. This was also accompanied by a 17% increase in whole-body energy expenditure ¹⁹.
6 The aim of the present study was, first, to examine whether giving this same dose of mirabegron
7 in combination with a cardioselective β_1 -AR antagonist could increase BAT oxidative metabolism
8 while blunting the cardiovascular responses. We were also interested in determining whether
9 inhibiting the β_1 -AR could increase the sensitivity of the β_2 - and β_3 -AR. We previously showed
10 that silencing the *ADRB2* *in vitro* resulted in a compensatory increase in the expression of *ADRB3*
11 ¹⁹. We therefore hypothesized that inhibiting the β_1 -AR would not only prevent the undesirable
12 cardiovascular responses, but also increase the stimulation of the β_2 -AR and β_3 -AR, thereby
13 allowing mirabegron to be administered at a lower or similar dose while eliciting similar or greater
14 thermogenic effects. Indeed, whether mirabegron was administered alone or in combination with
15 bisoprolol, energy expenditure increased above baseline levels (by 27% with mirabegron alone
16 and 11% with mirabegron and bisoprolol). Similar to our previous investigation, BAT oxidative
17 metabolism and BAT blood flow increased with the high dose of mirabegron administration.
18 However, in contrast to our hypothesis, this effect was blunted when mirabegron was administered
19 with bisoprolol. The exact cause of this reduction in BAT oxidative metabolism remains unclear.
20 One explanation could be that β_1 -AR inhibition, rather than potentiating the effect of mirabegron,
21 directly inhibited BAT oxidative metabolism. This would certainly be consistent with a previous
22 *in vitro* study, which showed that silencing *ADRB1* in immortalized human brown adipocytes
23 significantly attenuated *UCPI* induction in response to isoproterenol stimulation ³⁶. However, we

1 and others have shown that silencing *ADRB1* in human primary brown adipocytes has no effect on
2 cellular respiration, whether stimulated with norepinephrine ¹⁹ or not ³⁷. Alternatively, a more
3 plausible explanation is that the reduction in BAT blood flow when mirabegron was given with
4 bisoprolol restricted the ability for BAT to increase oxidative metabolism. Although adrenergic
5 stimulation can increase BAT blood flow, even in the absence of thermogenesis in mice ³⁸ and
6 humans ³⁹, the suppression of BAT blood flow in male Wistar rats has been shown to significantly
7 reduce the norepinephrine-stimulated increase in BAT temperature ⁴⁰. Evidence from the present
8 study suggest this may also be the case in humans.

9 Whether this reduction in BAT blood flow is a direct effect of β_1 -AR-antagonism on BAT
10 vasomotor tone or an indirect result of a possible decrease in cardiac output remains unclear. The
11 rate of glucose uptake was also reduced when bisoprolol was given with mirabegron, which may
12 have been partially mediated by the reduction in BAT blood flow. It should be noted that the rate
13 of glucose uptake was still significantly greater than what has been reported under unstimulated
14 room temperature conditions ($16 \pm 8 \text{ nmol}\cdot\text{g}^{-1}\cdot\text{min}^{-1}$ with mirabegron + bisoprolol vs $9 \pm 4 \text{ nmol}\cdot\text{g}^{-1}\cdot\text{min}^{-1}$
15 at room temperature; ⁴¹) or when given a therapeutic dose (50 mg) of mirabegron (9 ± 5
16 $\text{nmol}\cdot\text{g}^{-1}\cdot\text{min}^{-1}$; ¹⁹)

17 One noted secondary effect of mirabegron administration is the increase in systolic blood
18 pressure and heart rate when it is administered at the maximal allowable dose. Consistent with
19 previous findings, the administration of the maximal allowable dose of mirabegron increased
20 systolic blood pressure and heart rate by $5 \pm 5 \text{ mmHg}$ and $6 \pm 7 \text{ beats}\cdot\text{min}^{-1}$ above pre-treatment
21 levels, respectively. In contrast, when mirabegron was given with bisoprolol, heart rate and rate
22 pressure product (RPP), an indicator of myocardial oxygen consumption, decreased below baseline
23 levels. The reduction in RPP agrees with the results obtained by [¹¹C]acetate PET imaging of the

1 myocardium performed in a sub-group of participants, which showed a global reduction in
2 myocardial oxidative metabolism with bisoprolol. All these results were expected given the
3 cardioselective nature of the β_1 -AR antagonist used. The question remains whether this decrease
4 in myocardial metabolism and cardiovascular responses contributed to the reduction in BAT
5 thermogenesis.

6 In our previous investigation, we demonstrated that oral administration of mirabegron, not only
7 stimulated BAT thermogenesis, but also increased the systemic rate of appearance of NEFA and
8 glycerol, an indicator of whole-body WAT lipolysis, by 115% and 126%, respectively ¹⁹. The
9 increased WAT lipolysis far exceeded the rate of whole-body fatty acid oxidation. This suggested
10 that a significant proportion of the fatty acids released following the hydrolysis of intracellular
11 triglycerides were likely re-esterified *in situ*. We estimated that this energetically-costly
12 triglyceride hydrolysis-fatty acid re-esterification cycle, commonly referred to as the triglyceride-
13 fatty acid (TAG-FA) cycle or glycerolipid-free fatty acid (GL-FFA) cycle, accounted for 55% of
14 the mirabegron-stimulated increase in energy expenditure. In the present study, we did not observe
15 a significant increase in the systemic appearance of glycerol and NEFA. Consequently, we did not
16 observe significant changes in the TAG-FA cycle and therefore it was likely a minor contributor
17 to the increase in energy expenditure in the present study, accounting for 5.6% of the increase in
18 energy expenditure following mirabegron administration alone, and 19.6% when mirabegron was
19 given with bisoprolol. The slightly lower whole-body energy expenditure with mirabegron and
20 bisoprolol administration was also accompanied by a decrease in carbohydrate utilization, which
21 might reflect the transient decrease in the systemic rate of appearance of glucose.

22

23 **LIMITATIONS OF THE STUDY**

1 There are a few limitations to consider in the interpretation of our findings. First, this study
2 included a small number of young, healthy men. Only male participants were recruited, as the dose
3 given to stimulate BAT was 2-fold greater than the maximal allowable limit permitted for women
4 ³¹. In women, the ingestion of mirabegron is associated with a dose-dependent prolongation of the
5 QTc interval, thus restricting the maximum allowable dose to 100 mg. Further work is needed to
6 examine whether there are sex-dependent differences in mirabegron-mediated activation of BAT
7 metabolism. Second, the high dose of bisoprolol used significantly decreased heart rate and the
8 systolic blood pressure below baseline levels, which could have contributed to the observed
9 reduction in BAT blood flow and could have limited the ability to stimulate BAT thermogenesis.
10 The significant reduction in cardiovascular responses was somewhat limiting as there were
11 concerns with inducing significant levels of bradycardia. Indeed, of the 9 participants recruited
12 one participant with a particularly low resting heart rate (45 bpm) was precluded from completing
13 the mirabegron + bisoprolol condition as there were concerns about further decreasing his heart
14 rate. Finally, the PET/CT scanner used in the present study has a relatively large field of view (26
15 cm), which for the first time, allowed for the simultaneous quantification of BAT thermogenesis
16 and myocardial oxygen consumption in humans. However, in some of our taller participants, it
17 was not possible to image both the BAT and heart and therefore we prioritized the acquisition of
18 supraclavicular BAT. This resulted in an incomplete dataset of the [¹¹C]acetate PET
19 pharmacokinetic analysis of the myocardium.

20 **CONCLUSION**

21 In conclusion, as demonstrated in our previous study, a single maximal allowable dose of
22 mirabegron elicited a significant increase in human BAT thermogenesis and whole-body energy
23 expenditure. In contrast to our initial hypothesis, the addition of bisoprolol did reduce mirabegron-

- 1 stimulated BAT oxidative metabolism. Whether the attenuation in BAT blood flow induced by the
- 2 large dose of bisoprolol led to this reduction in mirabegron-stimulated BAT thermogenesis
- 3 remains to be determined. Further work is needed to determine the optimal pharmacological
- 4 approach to activate BAT thermogenesis in humans.

1 **Acknowledgements**

2 The authors would like to thank the participants of this study for their commitment and
3 collaboration. The authors thank Caroll-Lynn Thibodeau, Maude Gérard, Myriam Flipot, Éric
4 Lavallée, Esteban Espinosa, Christophe Noll and Lucie Bouffard for their excellent technical
5 assistance and Stephen C. Cunnane for the use of PMOD. This work was supported by the Québec
6 Network on Drug Research (RQRM), to A.Caron and D.P.Blondin as well as a grant from the
7 Natural Sciences and Engineering Research Council of Canada (NSERC Canada) to D.P.Blondin
8 (RGPIN-2019-05813). D.P. Blondin holds the GSK Chair in Diabetes of the Université de
9 Sherbrooke and a Fonds de Recherche du Québec-Santé (FRQS) J1 salary award. L. Dumont is
10 the recipient of an FRQS doctoral training award. A. Caron is supported by a Canada Research
11 Chair in Neurometabolic Pharmacology and an FRQS J1 salary award. A.C. Carpentier is
12 supported by a Canada Research Chair in the Molecular Imaging of Diabetes.

1 **Author Contributions**

2 Conceptualization, D.P.B and A.C.; Methodology, L.D., D.P.B, A.C., E.E.T., and A.C.C.;

3 Investigation, L.D., A.C., G.R., E.C., M.F., F.F., S.P., S.D., B.G., E.E.T., A.C.C., and D.P.B.;

4 Writing first draft, L.D. and D.P.B; Writing – review and editing, L.D., A.C., G.R., E.C., M.F.,

5 F.F., S.P., S.D., B.G., E.E.T., A.C.C., and D.P.B.; Visualization, L.D. and D.P.B; Funding

6 Acquisition, A.C. and D.P.B.

7

8 **Declaration of interests:** No conflicts of interest, financial or otherwise, related to this work are
9 declared by the authors.

10

1 **FIGURES**

2 **Figure 1. Study protocol.**

3 (A) Randomized crossover study (n=8) where participants received mirabegron (200 mg) without
4 or with bisoprolol (10 mg), with a one-week wash-out period between visits.

5 (B) Metabolic protocol for both study visits.

6

7 **Figure 2. Mirabegron increases BAT oxidative metabolism and glucose uptake but not in**
8 **combination with bisoprolol.**

9 (A) Circulating mirabegron levels following oral administration of mirabegron (M, 200 mg)
10 without or with bisoprolol (MB, 10 mg) in humans. [¹¹C]acetate (orange arrow) and 2-deoxy-2-
11 [¹⁸F]-fluoro-D-glucose ([¹⁸F]FDG, green arrow) radiotracers were injected 210 and 240 min after
12 oral administration of mirabegron or mirabegron + bisoprolol, respectively, followed by a dynamic
13 list-mode PET acquisition (n = 8).

14 (B and C) Whole body energy expenditure over time (B) and change from basal levels (C) in
15 response to oral administration of mirabegron (M, 200 mg) without or with bisoprolol (MB, 10 mg)
16 (n = 8). The effect of intervention was determined using two-way ANOVA for repeated-measures
17 with Bonferroni post hoc test. # $P \leq 0.05$, ‡ $P \leq 0.0001$.

18 (D-F) [¹¹C]acetate uptake rate (D, K_1), oxidative metabolism (E, k_2) and lipid synthesis (F, k_3) of
19 supraclavicular BAT at baseline (Control) and in response to oral administration of mirabegron
20 (M, 200 mg) without or with bisoprolol (MB, 10 mg). Outliers were identify using the Interquartile
21 Range Method. One outlier (white square) was detected and replaced by the mean of this group
22 and a previous study⁴².

1 (G) Change in supraclavicular BAT radiodensity from basal levels in responses to oral
2 administration of mirabegron (M, 200 mg) without or with bisoprolol (MB, 10 mg) (n = 8).

3 (H) Supraclavicular BAT, WAT, and skeletal muscle net glucose uptake in response to oral
4 administration of mirabegron (M, 200 mg) without or with bisoprolol (MB, 10 mg) (n = 8). Skeletal
5 muscle glucose uptake represents mean uptake of regions of interest drawn from *m. pectoralis*
6 *major*, *m. trapezius*, *m. deltoideus*, *m. sternocleidomastoid*, *m. levator scapulae*, *m. latissimus*
7 *dorsi*, and *m. erector spinae*.

8 (I) Cervico-thoracic PET images of [¹¹C]acetate (two right images) and [¹⁸F]FDG uptake in
9 response to oral administration of mirabegron (M, 200 mg) without or with bisoprolol (MB, 10
10 mg). PET images of [¹¹C]acetate taken at 210 min and [¹⁸F]FDG taken at 240 min in the same
11 participant are depicted in response to mirabegron without or with bisoprolol. White arrows
12 represent supraclavicular BAT depot and orange arrows represent heart.

13 Data presented as mean ± SD. A One-way ANOVA for repeated measures with Bonferroni *post*
14 *hoc* test was used to determine statistically significant differences between the basal and the two
15 treatment conditions. Difference between mirabegron without or with bisoprolol determined using
16 paired-sample t test.

17

18 **Figure 3. Mirabegron with bisoprolol suppressed the cardiovascular side effects of**
19 **mirabegron alone.**

20 (A-C) Change in systolic blood pressure (A), diastolic blood pressure (B), and heart rate (C) from
21 basal levels in response to oral administration of mirabegron (M, 200 mg) without or with
22 bisoprolol (MB,10 mg) (n = 8).

1 (D) Change in rate pressure product from basal levels in response to oral administration of
2 mirabegron (M, 200 mg) without or with bisoprolol (MB, 10 mg) (n = 8). The effect of intervention
3 was determined using two-way ANOVA for repeated-measures with Bonferroni post hoc test. # P
4 ≤ 0.05 .

5 (E) Blood flow (F) obtained from the [^{11}C]acetate analysis of three segments (LAD, RCA and
6 LCX) of the heart and total heart (Global) at baseline (Control) and in response to oral
7 administration of mirabegron (M, 200 mg) without or with bisoprolol (MB, 10 mg) (n = 5-6).

8 (F) [^{11}C]acetate uptake (K_I) of three segments (LAD, RCA and LCX) of the heart and total heart
9 (Global) at baseline (Control) and in response to oral administration of mirabegron (M, 200 mg)
10 without or with bisoprolol (MB, 10 mg) (n = 5-6).

11 (G) Oxidative metabolism (k_2) obtained from the [^{11}C]acetate analysis of three segments (LAD,
12 RCA and LCX) of the heart and total heart (Global) at baseline (Control) and in response to oral
13 administration of mirabegron (M, 200 mg) without or with bisoprolol (MB, 10 mg) (n = 5-6).

14 LAD: Left anterior descending artery; LCX: Left circumflex artery; RCA: Right coronary artery.

15 Data presented as mean \pm SD. Difference between mirabegron without or with bisoprolol
16 determined using paired-sample t test

17

18 **Figure 4. Mirabegron alone or in combination with bisoprolol did not impact the TAG/NEFA**
19 **cycling.**

20 (A and B) Change in systemic rate of appearance of glycerol over time (A) and change from basal
21 levels (B) in response to oral administration of mirabegron (M, 200 mg) without or with bisoprolol
22 (MB, 10 mg) as index of whole-body lipolysis (n = 8).

1 (C and D) Change in systemic rate of appearance of NEFA over time (C) and change from basal
2 levels (D) in response to oral administration of mirabegron (M, 200 mg) without or with bisoprolol
3 (MB, 10 mg) (n = 8).

4 (E and F) Change in whole-body fatty acid oxidation over time (E) and change from basal levels
5 (F) in response to of mirabegron (M, 200 mg) without or with bisoprolol (MB,10 mg) determined
6 by indirect calorimetry (n = 8). The effect of the intervention was determined using two-way
7 ANOVA for repeated-measures with Bonferroni post hoc test. # $P \leq 0.05$, § $P \leq 0.001$.

8 (G and H) Change in whole-body glucose utilization over time (G) and change from basal levels
9 (H) in response to mirabegron (M, 200 mg) without or with bisoprolol (MB,10 mg) determined by
10 indirect calorimetry (n = 8). The effect of intervention was determined using two-way ANOVA
11 for repeated-measures with Bonferroni post hoc test. # $P \leq 0.05$, § $P \leq 0.001$

12 (I) Change in total, intracellular, and extracellular triacylglycerol/fatty acid (TAG/FA) cycling
13 from basal levels in response to of mirabegron (M, 200 mg) without or with bisoprolol (MB,10
14 mg) (n = 8).

15 (J) Change in the energetic cost of total TAG/FA cycle (n = 8).

16 Data presented as mean \pm SD. Difference between mirabegron without or with bisoprolol
17 determined using paired-sample t test.

18

1 STAR METHODS

2 KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Biological Samples		
Human plasma samples	This paper	N/A
Human urine samples	This paper	N/A
Chemicals, Peptides, and Recombinant Proteins		
Myrbetriq (Mirabegron)	Astellas Pharma	N/A
Bisoprolol	Sandoz Canada	N/A
Critical commercial Assays		
Glycerol reagent set	Instruchemie, Sigma-Aldrich	Cat# 2913, Cat# F6428
NEFA C kit	Wako diagnostics, Randox laboratories	Cat# 434-91795, Cat# FA115
Software and Algorithms		
GraphPad Prism 8 for statistical analysis	GraphPad Software	RRID: SCR_002798
Adobe Photoshop	Adobe	https://www.adobe.com/
PMOD 3.7	PMOD Technologies LLC	RRID : SCR_016547
MATLAB R2019a	The MathWorks	RRID : SCR_001622
Other		
[¹¹ C]acetate, radiotracer	CIMS	N/A
[¹⁸ F]FDG, radiotracer	CIMS	N/A
[6,6- ² H ₂]-glucose, stable isotope tracer	ACP Chemicals	Cat# 1CDLM349
[U- ¹³ C]-palmitate, stable isotope tracer	Cambridge isotopes Laboratories	Cat# DLM-1229
[1,1,2,3,3- ² H ₅]-glycerol, stable isotope tracer	Cambridge isotopes Laboratories	Cat# DLM-1229
Vmax 29n (indirect calorimetry)	Sensormedics	N/A
Biograph Vision PET-CT scanner	Siemens Healthineers	N/A

3

4

1 **RESOURCE AVAILABILITY**

2 **Lead contact**

3 Further information and requests for resources and reagent should be directed to and will be
4 fulfilled by the lead contact, Denis P. Blondin (denis.p.blondin@usherbrooke.ca).

6 **Data and code availability**

7 The processed data generated during this study as well as the MATLAB code used to perform the
8 pharmacokinetic modeling of [¹⁸F]FDG and [¹¹C]acetate are available at
9 doi.org/10.5281/zenodo.5834789. Anonymized image files are voluminous and, therefore, not
10 deposited in any public repository, but can be made available on request to the lead contact
11 (denis.p.blondin@usherbrooke.ca).

13 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

14 **Human Subjects**

15 Eight healthy men aged 27 ± 3 years with a body mass index of 22.5 ± 1.7 km/m², body mass of
16 $74.1 \pm 3 < 5.8$ kg and body surface area of 2.27 ± 0.09 m² participated in this study. All participants
17 were informed of the methodology and informed written consent was obtained in accordance with
18 the Declaration of Helsinki. The protocol was approved by the Human Ethics Committee of the
19 Centre de recherche du Centre hospitalier universitaire de Sherbrooke and Health Canada provided
20 regulatory approval for the off-label use of mirabegron. The study was pre-registered on
21 ClinicalTrials.gov (NCT04823442). The inclusion criteria included: (i) male; (ii) age between 18
22 and 35 years; (iii) BMI < 30 kg/m²; (iv) normal fasting glucose (< 5.6 mmol/l); (v) normal glucose
23 tolerance (2 h post 75 g OGTT glucose < 7.8 mmol/l); (vi) HbA1c < 5.8%. Exclusion criteria

1 included: (i) overt cardiovascular disease as assessed by medical history, physical exam, and
2 abnormal ECG; (ii) treatment with any drug known to affect lipid or carbohydrate metabolism;
3 (iii) presence of liver disease, uncontrolled thyroid disorder, previous pancreatitis, bleeding
4 disorder, or other major illness; (iv) smoking (>1 cigarette/day) and/or consumption of 2 alcoholic
5 beverages per day; (v) prior history or current fasting plasma cholesterol level > 7 mmol/l or fasting
6 TG > 6 mmol/l.

7

8 **METHOD DETAILS**

9 **Experimental Protocols**

10 Participants took part in two experimental sessions assigned in a random order. Participants
11 ingested either 200 mg of the β_3 -AR agonist mirabegron (Myrbetriq, Astellas Pharma Canada)
12 alone or in combination with 10 mg of bisoprolol, a β_1 -AR antagonist. Each experimental session
13 consisted of a baseline period at ambient temperature ($\sim 22^\circ\text{C}$), followed by the oral administration
14 of the medication. In the mirabegron + bisoprolol condition, both medications were given
15 simultaneously, as the bisoprolol monogram provide to the FDA reports a t_{max} of 168 min, which
16 is 40 min earlier than the t_{max} of mirabegron (210 min). This would allow us to elicit the effects of
17 β_1 -AR antagonism prior to the full effect of mirabegron-mediated agonism. Experimental sessions
18 were conducted between 08.00 and 16.00 h at the Centre de recherche du Centre hospitalier
19 universitaire de Sherbrooke, following a 12 h fast and 48 h without strenuous physical activity.
20 Participants followed a 2-day standard isocaloric diet which was determined following 3-day food
21 record, accounting for the participant's standard daily physical activity level, determined by
22 wearing a portable arm band accelerometer for 3-days. Upon arriving to the laboratory, participants

1 emptied their bladder, then were weighed and indwelling catheters were placed in the antecubital
2 vein in both arms for blood sampling and tracer infusion.

3 **Metabolic Heat Production, Fuel Selection and Cardiovascular Measures**

4 Whole-body metabolic heat production and substrate utilization was determined by indirect
5 respiratory calorimetry (corrected for protein oxidation), measured every 60 min for a collection
6 period of 20 min ⁷. The molar rate of fatty acid oxidation ($\mu\text{mol}\cdot\text{min}^{-1}$) was calculated from
7 triglyceride oxidation ($\text{g}\cdot\text{min}^{-1}$) assuming the average molecular weight of triglyceride as 861
8 $\text{g}\cdot\text{mol}^{-1}$ and multiplying the molar rate of triglyceride oxidation by three, as three moles of fatty
9 acids are contained in each mole of triglyceride. Energy potentials of 16.3, 40.8 and 19.7 $\text{kJ}\cdot\text{g}^{-1}$
10 were used to calculate the amount of heat produced from glucose, lipid and protein oxidation,
11 respectively. Blood pressure and heart rate were measured every 60 min using an Omron blood
12 pressure monitor (HEM-790IT, Omron Healthcare).

13 **PET Imaging and Analysis**

14 Participants remained supine in a PET and CT scanner (Siemens Healthineers Biograph Vision)
15 for 30 min for the baseline and the final 90 min of the mirabegron treatment. Tissue-specific
16 oxidative metabolism was determined by first performing a CT scan (30 mAs) centered at the
17 cervico-thoracic region to correct for attenuation and define PET regions of interest (ROI). At time
18 -45 min (room temperature, before treatment) and at time 210 min (*i.e.* 210 min following oral
19 administration of mirabegron alone or in combination with bisoprolol), a ~ 175 MBq bolus of
20 [^{11}C]acetate was injected intravenously and was followed by a 20-min list-mode dynamic PET
21 acquisition (frames: 24 x 10 s, 12 x 30 s, 2 x 300 s) centered at the cervico-thoracic junction ⁷. A
22 ~ 125 MBq bolus of 2-deoxy-2- ^{18}F fluoro-D-glucose (^{18}F FDG) was intravenously injected 30
23 min after the [^{11}C]acetate injection at time 240 (*i.e.* 240 min following oral administration of

1 mirabegron alone or in combination with bisoprolol). followed by a list-mode dynamic PET
2 acquisition (frames: 12 x 10 s, 10 x 45 s, 7 x 90 s, 2 x 300 s) centered at the cervico-thoracic
3 junction. Residual [^{11}C]acetate activity prior to the [^{18}F]FDG scans were corrected by acquiring a
4 30 s frame prior to the injection of [^{18}F]FDG and accounting for the disintegration rate and
5 metabolic clearance of ^{11}C .

6 ROI were drawn from the transaxial CT slices then copied to the [^{11}C]acetate and [^{18}F]FDG PET
7 images. ROIs were drawn in the left ventricle for blood activity (image-derived arterial input
8 function, AIF), the larger skeletal muscles in the field of view (e.g. *m. sternocleidomastoid*, *m.*
9 *trapezius*, *m. pectoralis major*, *m. deltoideus*, *m. levator scapulae*, *m. latissimus dorsi*, *m. erector*
10 *spinea*), on posterior cervical subcutaneous adipose tissue and on supraclavicular BAT. The mean
11 standard uptake values (SUV_{mean}) from these ROIs were then extracted for each time frame using
12 PMOD (version 3.7, PMOD Technologies LLC) to create time-activity curves. The blood signal
13 for [^{11}C]acetate was then corrected to exclude the contribution of metabolites ⁴³. The metabolite-
14 corrected time-activity curves were then used to perform pharmacokinetic modeling in MATLAB
15 (The mathWorks, R2019a). A four-compartment, two-tissue, model²⁸ was applied to the
16 [^{11}C]acetate signal to derive the rates of uptake (K_1 in $\text{ml}\cdot\text{g}^{-1}\cdot\text{min}^{-1}$), oxidation (k_2 in min^{-1}) and
17 lipid synthesis (k_3 in min^{-1}). Plasma and tissue time-radioactivity curves for [^{18}F]FDG were
18 analyzed graphically using the Patlak linearization method ⁷. The glucose fractional uptake (K_i in
19 min^{-1}) is equal to the slope of the plot in the graphical analysis. Net glucose uptake (K_m in $\text{nmol}\cdot\text{g}^{-1}\cdot\text{min}^{-1}$)
20 $= (K_i \cdot \text{circulating glucose}) \cdot (\text{LC}^{-1}) \cdot (\text{tissue density} \cdot 1000)^{-1}$) was obtained by multiplying K_i by
21 circulating plasma glucose levels at the time of the PET image acquisition, which assumes a lump
22 constant (LC) value of 1.14 and 1.16 compared with endogenous plasma glucose for the BAT and
23 skeletal muscles, respectively, and corrected for a tissue density of 0.925 g/mL and 1.0597 g/mL.

1 **Whole-Body Lipolysis and Triacylglycerol/Fatty Acid Cycling**

2 Upon arriving to the laboratory, participants emptied their bladder and indwelling catheters were
3 placed in the antecubital vein in both arms for blood sampling and tracer infusions. A primed (30
4 $\mu\text{mol/kg}$) continuous infusion ($0.3 \mu\text{mol}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$) of $[6,6\text{-}^2\text{H}_2]$ -glucose was started 150 min
5 before oral administration of mirabegron or the combination of mirabegron and bisoprolol (time -
6 150 min) to determine the systemic rate of appearance of plasma glucose ($\text{Ra}_{\text{glucose}}$)⁷. Plasma
7 NEFA appearance rate (Ra_{NEFA}) and plasma glycerol appearance rate ($\text{Ra}_{\text{glycerol}}$) were determined
8 with a continuous infusion of $[\text{U-}^{13}\text{C}]$ -palmitate ($0.01 \mu\text{mol/kg/min}$ in 100 mL 25% human serum
9 albumin) and a primed ($1.6 \mu\text{mol}\cdot\text{kg}^{-1}$) continuous infusion ($0.05 \mu\text{mol/kg/min}$) of $[1,1,2,3,3\text{-}^2\text{H}_5]$ -
10 glycerol started 60 min before the oral administration of mirabegron or the combination of
11 mirabegron and bisoprolol (time - 60 min)⁷. Ra_{NEFA} was calculated by multiplying the plasma
12 palmitate appearance rate by the fractional contribution of palmitate to total plasma NEFA
13 concentrations.

14 Total, intracellular and extracellular triacylglycerol/fatty acid (TAG/FA) cycling was calculated
15 using $\text{Ra}_{\text{glycerol}}$, Ra_{NEFA} and the rate of fatty acid oxidation. In brief, total TAG/FA cycling was
16 calculated as the difference between the rate of fatty acid oxidation and the total amount of fatty
17 acids made available by the hydrolysis of intracellular triglycerides ($3 \times \text{Ra}_{\text{glycerol}}$), which is derived
18 primarily from WAT under fasted conditions. Since glycerol kinase has a low activity in WAT,
19 relative to other tissues, the glycerol produced following the complete hydrolysis of a triglyceride
20 in WAT is rapidly excreted into circulation where it can serve as gluconeogenic substrate.
21 Intracellular or primary TAG/FA cycling refers to the re-esterification of fatty acids within the cell
22 where it was hydrolyzed. This is calculated from the difference between the systemic rate of
23 appearance of NEFA (i.e. Ra_{NEFA}) and the total amount of fatty acids released following

1 intracellular hydrolysis of triglycerides ($3 \times R_{\text{glycerol}}$). Extracellular or secondary TAG/FA cycling
2 refers to the re-esterification of fatty acids after it has been released into the circulation, primarily
3 packaged by the liver into triglyceride-rich lipoproteins (very-low density lipoproteins; VLDL) or
4 intracellular lipid droplets. This is calculated from the difference between the total rate of fatty
5 acids oxidation and the systemic appearance of fatty acids (i.e. R_{NEFA}). The energy cost of
6 TAG/FA cycling was calculated assuming that the re-esterification of each triglyceride requires
7 ~ 8 ATP (or ~ 144 kcal·mol⁻¹ of triglyceride recycled), for the activation of each of the three fatty
8 acids (2 ATP per fatty acid), and glycerogenesis (~ 2 ATP) providing the three-carbon backbone
9 for triglyceride synthesis⁴⁴.

10

11 **Biological Assays**

12 Glucose, total NEFA, TG, cortisol, TSH, free T3 and free T4 were measured using specific
13 radioimmunoassay and colorimetric assays ⁷. Plasma C-peptide, GIP, total GLP-1, glucagon,
14 insulin, leptin and PYY were measured using Luminex xMAP-based immunoassays (Millipore,
15 Etobicoke, ON, Canada). Adiponectin, total and acylated ghrelin were measured by ELISA
16 (Alpco, Salem, NH, USA). Individual plasma NEFA (palmitate, linoleate, oleate), [U-¹³C]-
17 palmitate enrichment, [1,1,2,3,3-²H₅]-glycerol enrichment and [6,6-²H₂]-glucose enrichment were
18 measured by gas chromatography-mass spectrometry ⁷.

19

20 **QUANTIFICATION AND STATISTICAL ANALYSIS**

21 **Statistical Analyses**

22 Statistical analysis was performed using Prism (GraphPad; 8.0). Blood chemistry data are
23 expressed as mean with 95% CI or median with interquartile range otherwise the data are expressed

1 as mean \pm SD. The Shapiro-Wilk test was performed to verify the normality of data, when
2 necessary. Significance between groups was determined using 2-tailed paired Student's t test, or
3 one-way or two-way ANOVA when appropriate, with multiple comparisons using Bonferroni's
4 correction. The significance threshold was set at $P \leq 0.05$.

5 **ADDITIONAL RESOURCES**

6 ClinicalTrials.gov identifier NCT04823442

7

8

1 REFERENCES


- 2
- 3 1. Cannon, B., and Nedergaard, J. (2004). Brown Adipose Tissue: Function and
4 Physiological Significance. *Physiol Rev* 84, 277–359. 10.1152/physrev.00015.2003.
- 5 2. Trayhurn, P. (1979). Thermoregulation in the diabetic-obese (db/db) mouse. *Pflugers Arch*
6 380, 227–232. 10.1007/BF00582901.
- 7 3. Stanford, K.I., Middelbeek, R.J.W., Townsend, K.L., An, D., Nygaard, E.B., Hitchcox,
8 K.M., Markan, K.R., Nakano, K., Hirshman, M.F., Tseng, Y.-H., et al. (2013). Brown
9 adipose tissue regulates glucose homeostasis and insulin sensitivity. *Journal of Clinical*
10 *Investigation* 123, 215–223. 10.1172/JCI62308.
- 11 4. Feldmann, H.M., Golozoubova, V., Cannon, B., and Nedergaard, J. (2009). UCP1
12 Ablation Induces Obesity and Abolishes Diet-Induced Thermogenesis in Mice Exempt
13 from Thermal Stress by Living at Thermoneutrality. *Cell Metab* 9, 203–209.
14 10.1016/j.cmet.2008.12.014.
- 15 5. Berbée, J.F.P., Boon, M.R., Khedoe, P.P.S.J., Bartelt, A., Schlein, C., Worthmann, A.,
16 Kooijman, S., Hoeke, G., Mol, I.M., John, C., et al. (2015). Brown fat activation reduces
17 hypercholesterolaemia and protects from atherosclerosis development. *Nat Commun* 6,
18 6356. 10.1038/ncomms7356.
- 19 6. Carpentier, A.C., Blondin, D.P., Haman, F., and Richard, D. (2022). Brown adipose tissue
20 - a translational perspective. *Endocr Rev*. 10.1210/endrev/bnac015.
- 21 7. Ouellet, V., Labbé, S.M., Blondin, D.P., Phoenix, S., Guérin, B., Haman, F., Turcotte,
22 E.E., Richard, D., and Carpentier, A.C. (2012). Brown adipose tissue oxidative
23 metabolism contributes to energy expenditure during acute cold exposure in humans. *J*
24 *Clin Invest* 122, 545–552. 10.1172/JCI60433.
- 25 8. Becher, T., Palanisamy, S., Kramer, D.J., Eljalby, M., Marx, S.J., Wibmer, A.G., Butler,
26 S.D., Jiang, C.S., Vaughan, R., Schöder, H., et al. (2021). Brown adipose tissue is
27 associated with cardiometabolic health. *Nat Med* 27, 58–65. 10.1038/s41591-020-1126-7.
- 28 9. Blondin, D.P., Labbé, S.M., Noll, C., Kunach, M., Phoenix, S., Guérin, B., Turcotte, É.E.,
29 Haman, F., Richard, D., and Carpentier, A.C. (2015). Selective Impairment of Glucose but
30 Not Fatty Acid or Oxidative Metabolism in Brown Adipose Tissue of Subjects With Type
31 2 Diabetes. *Diabetes* 64, 2388–2397. 10.2337/db14-1651.
- 32 10. Blondin, D.P., Labbé, S.M., Phoenix, S., Guérin, B., Turcotte, É.E., Richard, D.,
33 Carpentier, A.C., and Haman, F. (2015). Contributions of white and brown adipose tissues
34 and skeletal muscles to acute cold-induced metabolic responses in healthy men. *J Physiol*
35 593, 701–714. 10.1113/jphysiol.2014.283598.
- 36 11. Blondin, D.P., Tingelstad, H.C., Noll, C., Frisch, F., Phoenix, S., Guérin, B., Turcotte,
37 É.E., Richard, D., Haman, F., and Carpentier, A.C. (2017). Dietary fatty acid metabolism
38 of brown adipose tissue in cold-acclimated men. *Nat Commun* 8, 14146.
39 10.1038/ncomms14146.
- 40 12. u Din, M., Raiko, J., Saari, T., Kudomi, N., Tolvanen, T., Oikonen, V., Teuvo, J., Sipilä,
41 H.T., Savisto, N., Parkkola, R., et al. (2016). Human brown adipose tissue [15O]O2 PET
42 imaging in the presence and absence of cold stimulus. *Eur J Nucl Med Mol Imaging* 43,
43 1878–1886. 10.1007/s00259-016-3364-y.
- 44 13. Hanssen, M.J.W., Hoeks, J., Brans, B., van der Lans, A.A.J.J., Schaart, G., van den
45 Driessche, J.J., Jörgensen, J.A., Boekschoten, M. v, Hesselink, M.K.C., Havekes, B., et al.

- 1 (2015). Short-term cold acclimation improves insulin sensitivity in patients with type 2
2 diabetes mellitus. *Nat Med* 21, 863–865. 10.1038/nm.3891.
- 3 14. Finlin, B.S., Memetimin, H., Confides, A.L., Kasza, I., Zhu, B., Vekaria, H.J., Harfmann,
4 B., Jones, K.A., Johnson, Z.R., Westgate, P.M., et al. (2018). Human adipose being in
5 response to cold and mirabegron. *JCI Insight* 3. 10.1172/jci.insight.121510.
- 6 15. Finlin, B.S., Memetimin, H., Zhu, B., Confides, A.L., Vekaria, H.J., el Khouli, R.H.,
7 Johnson, Z.R., Westgate, P.M., Chen, J., Morris, A.J., et al. (2020). The β 3-adrenergic
8 receptor agonist mirabegron improves glucose homeostasis in obese humans. *J Clin Invest*
9 130, 2319–2331. 10.1172/JCI134892.
- 10 16. O'Mara, A.E., Johnson, J.W., Linderman, J.D., Brychta, R.J., McGehee, S., Fletcher,
11 L.A., Fink, Y.A., Kapuria, D., Cassimatis, T.M., Kelsey, N., et al. (2020). Chronic
12 mirabegron treatment increases human brown fat, HDL cholesterol, and insulin
13 sensitivity. *J Clin Invest* 130, 2209–2219. 10.1172/JCI131126.
- 14 17. Cypess, A.M., Weiner, L.S., Roberts-Toler, C., Franquet Elía, E., Kessler, S.H., Kahn,
15 P.A., English, J., Chatman, K., Trauger, S.A., Doria, A., et al. (2015). Activation of
16 human brown adipose tissue by a β 3-adrenergic receptor agonist. *Cell Metab* 21, 33–38.
17 10.1016/j.cmet.2014.12.009.
- 18 18. Baskin, A.S., Linderman, J.D., Brychta, R.J., McGehee, S., Anflück-Chames, E., Cero, C.,
19 Johnson, J.W., O'Mara, A.E., Fletcher, L.A., Leitner, B.P., et al. (2018). Regulation of
20 Human Adipose Tissue Activation, Gallbladder Size, and Bile Acid Metabolism by a β 3-
21 Adrenergic Receptor Agonist. *Diabetes* 67, 2113–2125. 10.2337/db18-0462.
- 22 19. Blondin, D.P., Nielsen, S., Kuipers, E.N., Severinsen, M.C., Jensen, V.H., Miard, S.,
23 Jespersen, N.Z., Kooijman, S., Boon, M.R., Fortin, M., et al. (2020). Human Brown
24 Adipocyte Thermogenesis Is Driven by β 2-AR Stimulation. *Cell Metab* 32, 287-300.e7.
25 10.1016/j.cmet.2020.07.005.
- 26 20. Sacco, E., and Bientinesi, R. (2012). Mirabegron: a review of recent data and its prospects
27 in the management of overactive bladder. *Ther Adv Urol* 4, 315–324.
28 10.1177/1756287212457114.
- 29 21. van Gelderen, M., Stölzel, M., Meijer, J., Kerbusch, V., Collins, C., and Korstanje, C.
30 (2017). An Exploratory Study in Healthy Male Subjects of the Mechanism of Mirabegron-
31 Induced Cardiovascular Effects. *J Clin Pharmacol* 57, 1534–1544. 10.1002/jcph.952.
- 32 22. Malik, M., van Gelderen, E.M., Lee, J.H., Kowalski, D.L., Yen, M., Goldwater, R.,
33 Mujais, S.K., Schaddelee, M.P., de Koning, P., Kaibara, A., et al. (2012). Proarrhythmic
34 safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind,
35 placebo-, and active-controlled thorough QT study. *Clin Pharmacol Ther* 92, 696–706.
36 10.1038/clpt.2012.181.
- 37 23. Ihl-Vahl, R. (1996). Differential Regulation of mRNA Specific for β 1- and β 2-adrenergic
38 Receptors in Human Failing Hearts. Evaluation of the Absolute Cardiac mRNA Levels by
39 Two Independent Methods. *J Mol Cell Cardiol* 28, 1–10. 10.1006/jmcc.1996.0001.
- 40 24. Schobesberger, S., Wright, P.T., Poulet, C., Sanchez Alonso Mardones, J.L., Mansfield,
41 C., Friebe, A., Harding, S.E., Balligand, J.-L., Nikolaev, V.O., and Gorelik, J. (2020). β 3-
42 Adrenoceptor redistribution impairs NO/cGMP/PDE2 signalling in failing
43 cardiomyocytes. *Elife* 9. 10.7554/eLife.52221.
- 44 25. Arch, J.R.S. (2011). Challenges in β 3-adrenoceptor agonist drug development. *Ther Adv*
45 *Endocrinol Metab* 2, 59–64. 10.1177/2042018811398517.


- 1 26. Tran, K.-V., Brown, E.L., DeSouza, T., Jespersen, N.Z., Nandrup-Bus, C., Yang, Q.,
2 Yang, Z., Desai, A., Min, S.Y., Rojas-Rodriguez, R., et al. (2020). Human thermogenic
3 adipocyte regulation by the long noncoding RNA LINC00473. *Nat Metab* 2, 397–412.
4 10.1038/s42255-020-0205-x.
- 5 27. Cero, C., Lea, H.J., Zhu, K.Y., Shamsi, F., Tseng, Y.-H., and Cypess, A.M. (2021). β 3-
6 Adrenergic receptors regulate human brown/beige adipocyte lipolysis and thermogenesis.
7 *JCI Insight* 6. 10.1172/jci.insight.139160.
- 8 28. Richard, M.A., Blondin, D.P., Noll, C., Lebel, R., Lepage, M., and Carpentier, A.C.
9 (2019). Determination of a pharmacokinetic model for [11C]-acetate in brown adipose
10 tissue. *EJNMMI Res* 9, 31. 10.1186/s13550-019-0497-6.
- 11 29. Orava, J., Nuutila, P., Lidell, M.E., Oikonen, V., Nojonen, T., Viljanen, T., Scheinin, M.,
12 Taittonen, M., Niemi, T., Enerbäck, S., et al. (2011). Different metabolic responses of
13 human brown adipose tissue to activation by cold and insulin. *Cell Metab* 14, 272–279.
14 10.1016/j.cmet.2011.06.012.
- 15 30. O’Mara, A.E., Johnson, J.W., Linderman, J.D., Brychta, R.J., McGehee, S., Fletcher,
16 L.A., Fink, Y.A., Kapuria, D., Cassimatis, T.M., Kelsey, N., et al. (2020). Chronic
17 mirabegron treatment increases human brown fat, HDL cholesterol, and insulin
18 sensitivity. *Journal of Clinical Investigation* 130, 2209–2219. 10.1172/JCI131126.
- 19 31. FDA (2012). Advisory committee briefing document mirabegron (YM178) for the
20 treatment of overactive bladder.
- 21 32. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. (1999).
22 *Lancet* 353, 9–13.
- 23 33. Nelson, R.R., Gobel, F.L., Jorgensen, C.R., Wang, K., Wang, Y., and Taylor, H.L. (1974).
24 Hemodynamic predictors of myocardial oxygen consumption during static and dynamic
25 exercise. *Circulation* 50, 1179–1189. 10.1161/01.cir.50.6.1179.
- 26 34. Gobel, F.L., Norstrom, L.A., Nelson, R.R., Jorgensen, C.R., and Wang, Y. (1978). The
27 rate-pressure product as an index of myocardial oxygen consumption during exercise in
28 patients with angina pectoris. *Circulation* 57, 549–556. 10.1161/01.CIR.57.3.549.
- 29 35. Schnabel, P., Maack, C., Mies, F., Tyroller, S., Scheer, A., and Böhm, M. (2000). Binding
30 Properties of β -Blockers at Recombinant β 1-, β 2-, and β 3-Adrenoceptors. *J Cardiovasc*
31 *Pharmacol* 36, 466–471. 10.1097/00005344-200010000-00008.
- 32 36. Riis-Vestergaard, M.J., Richelsen, B., Bruun, J.M., Li, W., Hansen, J.B., and Pedersen,
33 S.B. (2020). Beta-1 and Not Beta-3 Adrenergic Receptors May Be the Primary Regulator
34 of Human Brown Adipocyte Metabolism. *J Clin Endocrinol Metab* 105, e994–e1005.
35 10.1210/clinem/dgz298.
- 36 37. Cero, C., Lea, H.J., Zhu, K.Y., Shamsi, F., Tseng, Y.-H., and Cypess, A.M. (2021). β 3-
37 Adrenergic receptors regulate human brown/beige adipocyte lipolysis and thermogenesis.
38 *JCI Insight* 6. 10.1172/jci.insight.139160.
- 39 38. Abreu-Vieira, G., Hagberg, C.E., Spalding, K.L., Cannon, B., and Nedergaard, J. (2015).
40 Adrenergically stimulated blood flow in brown adipose tissue is not dependent on
41 thermogenesis. *Am J Physiol Endocrinol Metab* 308, E822-9.
42 10.1152/ajpendo.00494.2014.
- 43 39. Blondin, D.P., Frisch, F., Phoenix, S., Guérin, B., Turcotte, É.E., Haman, F., Richard, D.,
44 and Carpentier, A.C. (2017). Inhibition of Intracellular Triglyceride Lipolysis Suppresses
45 Cold-Induced Brown Adipose Tissue Metabolism and Increases Shivering in Humans.
46 *Cell Metab* 25, 438–447. 10.1016/j.cmet.2016.12.005.


- 1 40. Nagashima, T., Ohinata, H., and Kuroshima, A. (1994). Involvement of nitric oxide in
2 noradrenaline-induced increase in blood flow through brown adipose tissue. *Life Sci* 54,
3 17–25. 10.1016/0024-3205(94)00573-7.
- 4 41. Orava, J., Nuutila, P., Lidell, M.E., Oikonen, V., Noponen, T., Viljanen, T., Scheinin, M.,
5 Taittonen, M., Niemi, T., Enerbäck, S., et al. (2011). Different metabolic responses of
6 human brown adipose tissue to activation by cold and insulin. *Cell Metab* 14, 272–279.
7 10.1016/j.cmet.2011.06.012.
- 8 42. Richard, G., Blondin, D.P., Syed, S.A., Rossi, L., Fontes, M.E., Fortin, M., Phoenix, S.,
9 Frisch, F., Dubreuil, S., Guérin, B., et al. (2022). High-fructose feeding suppresses cold-
10 stimulated brown adipose tissue glucose uptake independently of changes in
11 thermogenesis and the gut microbiome. *Cell Rep Med* 3, 100742.
12 10.1016/j.xcrm.2022.100742.
- 13 43. Buck, A., Wolpers, H.G., Hutchins, G.D., Savas, V., Mangner, T.J., Nguyen, N., and
14 Schwaiger, M. (1991). Effect of carbon-11-acetate recirculation on estimates of
15 myocardial oxygen consumption by PET. *J Nucl Med* 32, 1950–1957.
- 16 44. Wolfe, R.R., and Chinkes, D.L. (2005). *Isotope Tracers in Metabolic Research: Principles*
17 *and Practice of Kinetic Analysis* (Wiley-Liss).
- 18


A



B










Table 1. Participant characteristics

Participant Characteristics	Healthy men
N	8
Age (years)	27 ± 3
Height (cm)	181.5 ± 3.9
Mass (kg)	74.1 ± 5.8
BMI (kg/m²)	22.5 ± 1.7
Fat mass (kg)	19.6 ± 5.3
Lean mass (kg)	53.5 ± 6.1
Waist circumference (cm)	80.8 ± 6.9
Hip circumference (cm)	98.4 ± 4.0
Body fat (%)	26.6 ± 5.3

BMI, Body Mass Index

Data expressed as mean ± SD

Table 2. Hormone and metabolite concentrations at baseline or with the ingestion of 200 mg mirabegron without or with 10 mg of bisoprolol

	Mirabegron		Mirabegron + Bisoprolol	
	Baseline	Intervention	Baseline	Intervention
EE (kcal/h)	68.2 (63.9-72.6)	86.4 (79.4-93.5) ^b	71.1 (66.1-76.1)	77.1 (65.3-88.9)
R_aglucose (μmol/min)	1,147 (681-1,614)	741 (385-1,096) ^b	1,054 (681-1,426)	580 (267-894) ^b
Glucose (mmol/L)	4.6 (4.3-4.9)	4.3 (4.0-4.6) ^a	4.5 (4.4-4.6)	4.3 (4.1-4.5)
NEFA (μmol/L)	295 (199-391)	700 (539-861) ^b	270 (165-375)	715 (503-927) ^b
TG (mmol/L)	0.7 (0.5-0.8)	0.5 (0.4-0.6) ^b	0.7 (0.6-0.8)	0.6 (0.5-0.8) ^d
Insulin (pmol/L)	59.9 (21.3-98.6)	65.9 (21.7-110.2)	62.7 (23.4-102.0)	52.9 (15.9-89.8)
Glucagon (pg/mL)	29.9 (16.4-43.4)	31.3 (13.2-49.4)	33.4 (45.8-21.1)	33.3 (23.5-43.2)
C-peptide (nmol/L)	0.3 (0.2-0.3)	0.3 (0.2-0.3)	0.2 (0.2-0.3)	0.2 (0.2-0.3)
TSH (IU/L)	2.1 (1.3-2.9)	1.5 (1.0-2.0) ^b	1.9 (1.2-2.5)	1.2 (0.9-1.5) ^b
Free T3 (pmol/L)	5.1 (4.6-5.6)	5.0 (4.4-5.5)	5.1 (4.6-5.5)	4.8 (4.3-5.3) ^a
Free T4 (pmol/L)	17.3 (15.7-18.8)	18.1 (16.6-19.6) ^c	17.2 (15.5-18.8)	17.7 (16.4-19.0) ^{a,d}
Cortisol (nmol/L)	337 (254-420)	174 (141-206) ^b	349 (291-406)	173 (117-228) ^b
Leptin (ng/mL)	0.8 (0.4-1.2)	0.6 (0.2-0.9) ^b	1.1 (0.4-1.7)	0.8 (0.2-1.3) ^{c,e}
GIP (pmol/L)	5.6 [3.1-10.7]	3.8 [2.5-5.4] ^b	6.0 (4.5-7.4)	4.4 (2.3-6.6)
Total GLP-1 (pmol/L)	28.6 (19.3-38.0)	29.4 (16.7-42.0)	30.2 (18.6-41.8)	30.0 (18.9-41.1)

Values are means with 95% confidence interval (CI) in parentheses for normally distributed data and median [interquartile range] for nonparametric data. Two-way ANOVA for repeated-measures with Bonferroni post hoc test.

^aEffect of intervention, $p \leq 0.05$

^b $p < 0.01$

^c $p < 0.001$

^dDifference without or with bisoprolol, $p \leq 0.05$

^e $p < 0.01$